High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics.
Standard
High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics. / Harris, M J; Panton, D; Caligiuri, M P; Krüll, Andreas; Tran-Johnson, T K; Jeste, D V.
In: PSYCHOPHARMACOL BULL, Vol. 28, No. 1, 1, 1992, p. 87-92.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics.
AU - Harris, M J
AU - Panton, D
AU - Caligiuri, M P
AU - Krüll, Andreas
AU - Tran-Johnson, T K
AU - Jeste, D V
PY - 1992
Y1 - 1992
N2 - We are conducting a prospective study of tardive dyskinesia (TD) in psychiatric patients over age 45, a large proportion of whom have had less than 1 month of total lifetime neuroleptic exposure. Patients are treated with the lowest effective dose of either haloperidol (usually 1-3 mg daily) or thioridazine (usually 25-75 mg daily). Patients are reexamined 1 month and 3 months after initial assessment and then at 3-month intervals. To date, a total of 68 patients (mean age 69.5 years) have been evaluated. Survival analysis showed a 27 percent cumulative incidence of TD (the 95% confidence interval being 14% to 40%) with 6 months of neuroleptic treatment in the study. The TD and non-TD patients did not differ on demographic and baseline clinical measures. Instrumental assessment showed that a greater proportion of TD patients had subclinical evidence of dyskinesia prior to the institution of neuroleptics, compared with non-TD patients.
AB - We are conducting a prospective study of tardive dyskinesia (TD) in psychiatric patients over age 45, a large proportion of whom have had less than 1 month of total lifetime neuroleptic exposure. Patients are treated with the lowest effective dose of either haloperidol (usually 1-3 mg daily) or thioridazine (usually 25-75 mg daily). Patients are reexamined 1 month and 3 months after initial assessment and then at 3-month intervals. To date, a total of 68 patients (mean age 69.5 years) have been evaluated. Survival analysis showed a 27 percent cumulative incidence of TD (the 95% confidence interval being 14% to 40%) with 6 months of neuroleptic treatment in the study. The TD and non-TD patients did not differ on demographic and baseline clinical measures. Instrumental assessment showed that a greater proportion of TD patients had subclinical evidence of dyskinesia prior to the institution of neuroleptics, compared with non-TD patients.
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Risk Factors
KW - Prospective Studies
KW - Age Factors
KW - Follow-Up Studies
KW - Incidence
KW - Dyskinesia, Drug-Induced/epidemiology
KW - Haloperidol/adverse effects
KW - Thioridazine/adverse effects
KW - Humans
KW - Male
KW - Female
KW - Middle Aged
KW - Risk Factors
KW - Prospective Studies
KW - Age Factors
KW - Follow-Up Studies
KW - Incidence
KW - Dyskinesia, Drug-Induced/epidemiology
KW - Haloperidol/adverse effects
KW - Thioridazine/adverse effects
M3 - SCORING: Journal article
VL - 28
SP - 87
EP - 92
IS - 1
M1 - 1
ER -